Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence

Military Medical Research, Journal Year: 2025, Volume and Issue: 12(1)

Published: Feb. 11, 2025

Abstract Cancer recurrence, driven by the phenomenon of tumor dormancy, presents a formidable challenge in oncology. Dormant cancer cells have ability to evade detection and treatment, leading relapse. This review emphasizes urgent need comprehend dormancy its implications for recurrence. Despite notable advancements, significant gaps remain our understanding mechanisms underlying lack reliable biomarkers predicting provides comprehensive analysis cellular, angiogenic, immunological aspects dormancy. It highlights current therapeutic strategies targeting dormant cells, particularly combination therapies immunotherapies, which hold promise preventing By elucidating these proposing innovative research methodologies, this aims deepen ultimately facilitating development more effective recurrence improving patient outcomes.

Language: Английский

---

Exploring the therapeutic potential of quercetin in cancer treatment: Targeting long non-coding RNAs

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 260, P. 155374 - 155374

Published: May 29, 2024

Language: Английский

---

Upregulated long non-coding RNAs TMPO-AS1, DDX11-AS1, and POLE gene expression predict poor prognosis in head and neck squamous cell carcinoma (HNSCC)

Gene Reports, Journal Year: 2024, Volume and Issue: 36, P. 101942 - 101942

Published: May 31, 2024

Language: Английский

---

The epigenetic regulatory network of long noncoding RNAs in hepatocellular carcinoma

Genes & Diseases, Journal Year: 2025, Volume and Issue: unknown, P. 101534 - 101534

Published: Jan. 1, 2025

Language: Английский

---

OTUD6B-AS1: a multifaceted regulator of cancer with critical clinical implications

American Journal of Cancer Research, Journal Year: 2025, Volume and Issue: 15(1), P. 1 - 18

Published: Jan. 1, 2025

OTU Deubiquitinase 6B-Antisense Transcript 1 (OTUD6B-AS1), a novel long non-coding RNA (lncRNA), has recently emerged as critical regulator in various tumors. Current research underscores its dual functionality, acting either an oncogene or tumor suppressor depending on the context. In this work, we compile and discuss findings from range of studies investigating expression patterns OTUD6B-AS1 different cancers consequent effects behavior, both vitro vivo. We delve into mechanisms through which influences cancer initiation progression, focusing role regulating essential cellular processes such cell growth, migration, invasion, angiogenesis, ferroptosis, treatment resistance. Operating complex interactions with microRNAs (miRNAs), proteins, pivotal signaling pathways - most notably Wnt/β-catenin exhibits variable roles across types environments. Additionally, assess clinical relevance levels, evaluating potential biomarker for prognosis diagnosis, well target therapeutic intervention. By consolidating existing knowledge, work aims to highlight implications encourage further oncology, ultimately contributing advancement targeted therapies.

Language: Английский

---

GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3078 - 3078

Published: March 27, 2025

Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality, influenced by both genetic epigenetic factors. Long non-coding RNAs (lncRNAs) such as GAS5 CASC8 have been implicated in susceptibility. This study aimed to assess the association rs145204276 ins/del rs10505477 A>G polymorphisms with CRC risk Romanian population. A case-control was conducted, including 156 patients 195 healthy controls. Genotyping for performed using real-time PCR, evaluated logistic regression calculate odds ratios (OR) 95% confidence intervals (CI). The carriers del allele significantly associated increased (OR: 2.13, CI: 1.24-3.63, p = 0.005) dominant model. In subgroup analysis, polymorphism restricted distal colon cases 2.98, 1.57-5.66, 0.001), advanced tumor stages (III + IV) 2.54, 1.31-4.91, 0.007), poorly differentiated tumors (G3) 3.98, 1.49-10.59, 0.009). No significant correlation found polymorphism. may influence susceptibility, particularly stages. However, showed no this cohort.

Language: Английский

---

A novel cancer-associated lncRNA, LINC01123, participates in tumor progression, metabolism, immune escape, and resistance

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 4, 2025

Long Intergenic Non-Protein Coding RNA 1123 (LINC01123), located on human chromosome 2q13, is a pivotal factor in tumorigenesis, exerting multifaceted oncogenic effects. Its expression strongly correlates with clinicopathological features, patient survival, and disease progression. In vivo vitro experiments further demonstrate that LINC01123 influences diverse cellular processes, including proliferation, apoptosis, viability, migration, invasion, stemness, tumor growth. Notably, it also regulates metabolic reprogramming, immune escape, cell resistance to treatment. regulated by multiple transcription factors participates gene regulation through protein interactions competitive endogenous (ceRNA) networks, thereby modulating cancer-promoting This work systematically elucidates its primary functions molecular mechanisms driving cancer initiation progression, suggesting might serve as novel potential driver biomarker various cancers.

Language: Английский

---

Long noncoding RNAs in ubiquitination, protein degradation, and human diseases

Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, Journal Year: 2024, Volume and Issue: unknown, P. 195061 - 195061

Published: Sept. 1, 2024

Language: Английский

---